phosphonoacetic acid has been researched along with Melanoma in 14 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 9.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Twenty-two patients with advanced malignant melanoma were entered in a pilot study receiving combination chemotherapy with PALA, vindesine, and cisplatin (PVP)." | 7.67 | PALA, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma. A pilot study. ( Kleeberg, UR; Voigt, H, 1984) |
| " In the human melanoma cell lines IGR3 and M5 the main metabolite of 5FU was 5-fluorouridine, while in the murine B16 melanoma only a small amount of 5-fluorouridine was formed." | 7.67 | Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars. ( Lankelma, J; Laurensse, E; Leyva, A; Peters, GJ; Pinedo, HM, 1984) |
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 5.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Twenty-two patients with advanced malignant melanoma were entered in a pilot study receiving combination chemotherapy with PALA, vindesine, and cisplatin (PVP)." | 3.67 | PALA, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma. A pilot study. ( Kleeberg, UR; Voigt, H, 1984) |
| " To test this hypothesis we examined the effects of PALA and nitrobenzylthioinosine (NBMPR) alone and in combination on B16 melanoma cells in vitro using a clonogenic assay and in vivo using growth delay." | 3.67 | Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine. ( Erlichman, C; Vidgen, D, 1984) |
| " In the human melanoma cell lines IGR3 and M5 the main metabolite of 5FU was 5-fluorouridine, while in the murine B16 melanoma only a small amount of 5-fluorouridine was formed." | 3.67 | Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars. ( Lankelma, J; Laurensse, E; Leyva, A; Peters, GJ; Pinedo, HM, 1984) |
| "Another solid tumor, Ridgway osteogenic sarcoma, which is sensitivie to many established chemotherapeutic agents, did not respond to PALA." | 1.26 | Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. ( Goldin, A; Inouye, T; Johnson, RK; Stark, GR, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (92.86) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peters, GJ | 2 |
| Laurensse, E | 2 |
| Leyva, A | 3 |
| Pinedo, HM | 3 |
| Kleeberg, UR | 2 |
| Mulder, JH | 1 |
| Rümke, P | 1 |
| Thomas, D | 1 |
| Rozencweig, M | 1 |
| Voigt, H | 1 |
| Erlichman, C | 3 |
| Vidgen, D | 1 |
| Lankelma, J | 2 |
| Donehower, RC | 1 |
| Speyer, JL | 1 |
| Klecker, R | 1 |
| Chabner, BA | 1 |
| Appel, H | 1 |
| Smith, P | 1 |
| Karle, JM | 1 |
| Anderson, LW | 1 |
| Cysyk, RL | 1 |
| Johnson, RK | 2 |
| Swyryd, EA | 1 |
| Stark, GR | 3 |
| Inouye, T | 1 |
| Goldin, A | 1 |
| McMillan, TJ | 1 |
| Kalebic, T | 1 |
| Hart, IR | 1 |
| Cillo, C | 1 |
| Dick, JE | 1 |
| Ling, V | 1 |
| Hill, RP | 1 |
| Morton, RF | 1 |
| Creagan, ET | 1 |
| Cullinan, SA | 1 |
| Mailliard, JA | 1 |
| Ebbert, L | 1 |
| Veeder, MH | 1 |
| Chang, M | 1 |
| Chan, TC | 1 |
| Young, B | 1 |
| King, ME | 1 |
| Taetle, R | 1 |
| Howell, SB | 1 |
1 trial available for phosphonoacetic acid and Melanoma
| Article | Year |
|---|---|
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cimetidine; Drug Evaluation; | 1987 |
13 other studies available for phosphonoacetic acid and Melanoma
| Article | Year |
|---|---|
Fluctuations in phosphoribosyl pyrophosphate levels in monolayer tumor cell lines. Effects of drugs.
Topics: Animals; Aspartic Acid; Buffers; Cell Line; Cytological Techniques; Fibroblasts; Humans; Melanoma; M | 1984 |
N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Drug Eruptions; Drug Evaluation; Female; Humans; | 1982 |
PALA, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma. A pilot study.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bone Marrow; C | 1984 |
Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1984 |
Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars.
Topics: Animals; Aspartic Acid; Cell Line; Cells, Cultured; Chromatography; Deoxyuracil Nucleotides; Fluorod | 1984 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Cell Division; Cell L | 1981 |
Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Colonic Neoplasms; Drug Evaluation; Humans; Melanoma | 1980 |
Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Cells, Cult | 1978 |
Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamyl Phosphate; D | 1976 |
High frequency of double drug resistance in the B16 melanoma cell line.
Topics: Amides; Animals; Antineoplastic Agents; Aspartic Acid; Cell Line; Colony-Forming Units Assay; Drug R | 1990 |
Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines.
Topics: Animals; Aspartic Acid; Cell Line; Drug Resistance; Gene Amplification; Mathematics; Melanoma; Metho | 1987 |
Modulation of the activity of PALA by dipyridamole.
Topics: Animals; Aspartic Acid; Biological Transport; Cell Line; Colonic Neoplasms; Dipyridamole; Drug Inter | 1985 |